{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:13:21Z","timestamp":1788578001704,"version":"build-2803163510"},"reference-count":17,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Complete remission (CR) rates for patients with acute myeloid leukaemia (AML) treated with intensive chemotherapy (IC) have increasingly improved. Yet, relapse remains a concern with a dismal prognosis. In this report, results are presented of a retrospective analysis comparing salvage therapy based on intermediate (I) or high (H)\u2010dose cytarabine (DAC) (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009203) and venetoclax\u2010azacitidine (VEN\u2010AZA) (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009114) for patients with AML in first relapse. Patients (median age 60\u2009years, interquartile range [IQR] 48\u201367) had reached CR1 after a standard 7\u2009+\u20093 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009305) or CPX351 schedule (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200912). I\/HDAC\u2010based and VEN\u2010AZA salvage, respectively, resulted in CR2 in 66.0% and 66.7% of the patients (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.96). Allogeneic haematopoietic stem cell transplantation (allo\u2010HSCT) was performed for 115 patients in CR2 and 18 in failure. Relapse\u2010free survival was 13.2 (IQR 7.0\u2010not reached [NR]) and 13.7 (IQR 7.8\u2010NR) months while overall survival (OS) was 14.5 (IQR 6.2\u2010NR) and 12.3\u2009months (IQR 4.8\u2010NR;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.41) for patients who received I\/HDAC\u2010based salvage and VEN\u2010AZA respectively. In multivariable analysis, relapsing patients \u226560\u2009years with low\/intermediate\u2010risk cytogenetics and VEN\u2010AZA had a better OS (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002), while I\/HDAC was more efficient for those with poor risk cytogenetics and &lt;\u200960\u2010year\u2010old (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002). VEN\u2010AZA salvage therapy thus appears promising compared with conventional I\/HDAC\u2010based IC; this question warrants evaluation in randomized studies.\n                  <\/jats:p>","DOI":"10.1111\/bjh.70815","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:00:02Z","timestamp":1788577202000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of venetoclax and azacitidine versus a cytarabine\u2010based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real\u2010world study of the\n                    <scp>DATAML<\/scp>\n                    \u2010\n                    <scp>IPC<\/scp>\n                    \u2010\n                    <scp>AURAML<\/scp>\n                    consortium"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0119-3548","authenticated-orcid":false,"given":"Pierre\u2010Yves","family":"Dumas","sequence":"first","affiliation":[{"name":"Univ. Bordeaux, INSERM, BRIC, U1312, CHU Bordeaux, Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, CHU Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bertoli","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, CHU de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Service d'H\u00e9matologie  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"B\u00e9rard","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Public Health CERPOP, INSERM\u2010University of Toulouse III, Toulouse University Hospital (CHU)  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Santana","sequence":"additional","affiliation":[{"name":"Department of Hematology CH de Valence  Valence France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-8657","authenticated-orcid":false,"given":"Ma\u00ebl","family":"Heiblig","sequence":"additional","affiliation":[{"name":"Department of Hematology CHU Lyon Sud  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3123-4948","authenticated-orcid":false,"given":"Thibaut","family":"Leguay","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, BRIC, U1312, CHU Bordeaux, Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, CHU Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Tavitian","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, CHU de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Service d'H\u00e9matologie  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8607-1955","authenticated-orcid":false,"given":"Estelle","family":"Borgne","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, BRIC, U1312, CHU Bordeaux, Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, CHU Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Charlotte","family":"de Grande","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, BRIC, U1312, CHU Bordeaux, Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, CHU Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Sarry","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, CHU de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Service d'H\u00e9matologie  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyad","family":"Acheaibi","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, BRIC, U1312, CHU Bordeaux, Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, CHU Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5341-5427","authenticated-orcid":false,"given":"Laetitia","family":"Largeaud","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, CHU de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Service d'H\u00e9matologie  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1239-1154","authenticated-orcid":false,"given":"Morgane","family":"Sighieri","sequence":"additional","affiliation":[{"name":"Aix\u2010Marseille University, INSERM U1068, CNRS, Institut Paoli\u2010Calmettes, CRCM  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4983-5581","authenticated-orcid":false,"given":"Emilie","family":"Klein","sequence":"additional","affiliation":[{"name":"Laboratoire d'H\u00e9matologie Biologique, CHU Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1447-8721","authenticated-orcid":false,"given":"Emmanuelle","family":"Tavernier","sequence":"additional","affiliation":[{"name":"Department of Hematology CHU de St Etienne  Saint\u2010Priest\u2010en\u2010Jarez France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Anne","family":"Hospital","sequence":"additional","affiliation":[{"name":"Aix\u2010Marseille University, INSERM U1068, CNRS, Institut Paoli\u2010Calmettes, CRCM  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-7654","authenticated-orcid":false,"given":"Martin","family":"Carr\u00e9","sequence":"additional","affiliation":[{"name":"Department of Hematology CHU de Grenoble  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9033-575X","authenticated-orcid":false,"given":"Gaspar Aspas","family":"Requena","sequence":"additional","affiliation":[{"name":"Department of Hematology CHU de Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9161-5141","authenticated-orcid":false,"given":"Anne","family":"Banos","sequence":"additional","affiliation":[{"name":"Department of Hematology CHG de Bayonne  Bayonne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Vey","sequence":"additional","affiliation":[{"name":"Aix\u2010Marseille University, INSERM U1068, CNRS, Institut Paoli\u2010Calmettes, CRCM  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5479-0261","authenticated-orcid":false,"given":"Arnaud","family":"Pigneux","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, BRIC, U1312, CHU Bordeaux, Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, CHU Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse, CHU de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Service d'H\u00e9matologie  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0081-1255","authenticated-orcid":false,"given":"Sylvain","family":"Garciaz","sequence":"additional","affiliation":[{"name":"Aix\u2010Marseille University, INSERM U1068, CNRS, Institut Paoli\u2010Calmettes, CRCM  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner H","year":"2022","journal-title":"Blood"},{"key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00277-018-3304-y","article-title":"Salvage regimens using conventional chemotherapy agents for relapsed\/refractory adult AML patients: a systematic literature review","volume":"97","author":"Meg\u00edas\u2010Vericat JE","year":"2018","journal-title":"Ann Hematol"},{"key":"e_1_2_11_4_1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo CD","year":"2020","journal-title":"N Engl J Med"},{"key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1016\/j.clml.2025.01.024","article-title":"A real\u2010world evaluation of frontline treatment for acute myeloid leukemia with azacitidine plus venetoclax","volume":"25","author":"Brandwein J","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41408-025-01344-3","article-title":"Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study","volume":"15","author":"Higu\u00e9 J","year":"2025","journal-title":"Blood Cancer J"},{"key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"103","author":"Aldoss I","year":"2018","journal-title":"Haematologica"},{"key":"e_1_2_11_8_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2\u2010inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo CD","year":"2018","journal-title":"Am J Hematol"},{"key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/ajh.25567","article-title":"Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"94","author":"Aldoss I","year":"2019","journal-title":"Am J Hematol"},{"key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3390\/cancers14082025","article-title":"Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients","volume":"14","author":"Garciaz S","year":"2022","journal-title":"Cancer"},{"key":"e_1_2_11_11_1","article-title":"Safety and efficacy: clinical experience of venetoclax in combination with hypomethylating agents in both newly diagnosed and relapsed\/refractory advanced myeloid malignancies","volume":"5","author":"Feld J","year":"2021","journal-title":"Hema"},{"key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1080\/10428194.2020.1761964","article-title":"Venetoclax is safe and efficacious in relapsed\/refractory AML","volume":"61","author":"Ganzel C","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_11_13_1","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/ejh.14140","article-title":"Azacitidine\u2010venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients","volume":"112","author":"Petit C","year":"2024","journal-title":"Eur J Haematol"},{"key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol F","year":"2015","journal-title":"Blood"},{"key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1002\/cncr.35214","article-title":"Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt","volume":"130","author":"Sedeta E","year":"2024","journal-title":"Cancer"},{"key":"e_1_2_11_16_1","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council adult and Children's Leukaemia working parties","volume":"92","author":"Grimwade D","year":"1998","journal-title":"Blood"},{"key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s12185-024-03835-8","article-title":"Recent advances in AML with mutated NPM1","volume":"120","author":"Ishikawa Y","year":"2024","journal-title":"Int J Hematol"},{"key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/bloodadvances.2023012062","article-title":"Guadecitabine vs TC in relapsed\/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL\u20102 trial","volume":"8","author":"Roboz GJ","year":"2024","journal-title":"Blood Adv"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70815","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70815","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:00:06Z","timestamp":1788577206000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":17,"alternative-id":["10.1111\/bjh.70815"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70815","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"2026-03-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bjh.70815"}}